458 related articles for article (PubMed ID: 26219978)
1. The molecular targets of approved treatments for pulmonary arterial hypertension.
Humbert M; Ghofrani HA
Thorax; 2016 Jan; 71(1):73-83. PubMed ID: 26219978
[TBL] [Abstract][Full Text] [Related]
2. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
3. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
[TBL] [Abstract][Full Text] [Related]
4. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
5. Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.
Bishop BM; Mauro VF; Khouri SJ
Pharmacotherapy; 2012 Sep; 32(9):838-55. PubMed ID: 22806762
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
[TBL] [Abstract][Full Text] [Related]
7. [Update: Current clinical developments in pulmonary hypertension].
Dumitrescu D; Ghofrani HA; Grimminger F; Hoeper MM; Rosenkranz S
Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S160-3. PubMed ID: 19718605
[TBL] [Abstract][Full Text] [Related]
8. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
[TBL] [Abstract][Full Text] [Related]
9. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.
Galiè N; Grimminger F; Grünig E; Hoeper MM; Humbert M; Jing ZC; Keogh AM; Langleben D; Rubin LJ; Fritsch A; Davie N; Ghofrani HA
J Heart Lung Transplant; 2017 May; 36(5):509-519. PubMed ID: 28190787
[TBL] [Abstract][Full Text] [Related]
11. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of pulmonary arterial hypertension].
Olschewski H; Ghofrani A; Enke B; Reichenberger F; Voswinckel R; Kreckel A; Ghofrani S; Wiedemann R; Schulz R; Grimminger F; Seeger W
Internist (Berl); 2005 Mar; 46(3):341-9. PubMed ID: 15703889
[TBL] [Abstract][Full Text] [Related]
13. [Targeted therapy of pulmonary arterial hypertension (PAH)].
Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
[No Abstract] [Full Text] [Related]
14. [Medical treatment of pulmonary hypertension: what's new?].
Richter MJ; Gall H; Tello K; Sommer N; Seeger W; Grimminger F; Ghofrani HA
Internist (Berl); 2015 May; 56(5):573-82. PubMed ID: 25924799
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of HIV-associated pulmonary hypertension.
Chinello P; Petrosillo N
Expert Rev Clin Pharmacol; 2016; 9(5):715-25. PubMed ID: 26863919
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies for treatment of pulmonary arterial hypertension.
Jasińska-Stroschein M; Orszulak-Michalak D
Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC
Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary arterial hypertension: a review in pharmacotherapy.
Patel BB; Feng Y; Cheng-Lai A
Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic treatment for pulmonary arterial hypertension.
Sastry BK
Curr Opin Cardiol; 2006 Nov; 21(6):561-8. PubMed ID: 17053404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
